Larotrectinib(Vitrakvi)

In 2018, the FDA approved larotrectinib, a prescription drug, for the U.S. market to target neurotrophic tyrosine receptor kinase (NTRK1, NTRK2, NTRK3) gene fusion proteins. Use under medical supervision.

Certificates related to Lucius

Drug Testing Report

Drug Approval Certificate

Target of Action

Fusion proteins of neurotrophic tyrosine receptor kinase (NTRK1, NTRK2, NTRK3) genes.

Dosage and Administration

Route and frequency of administration for larotrectinib: oral administration, 100 mg.

The dosage of larotrectinib should be adjusted according to the patient’s actual condition. For specific adjustments, consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Larotrectinib

Adverse Reactions

Common adverse reactions: elevated AST, anemia, vomiting.

Serious adverse reactions: central nervous system effects, bone fractures.

Reference article: Adverse Reactions of Larotrectinib

Use in Special Populations

Pregnancy: Women should be informed of the potential risk of this medicine to the fetus. Women of childbearing potential are advised to use effective contraceptive measures during treatment and for 1 week following the last dose of VITRAKVI.

Lactation: Women are advised not to breastfeed during treatment with VITRAKVI and for 1 week after the last dose.

Daily Precautions

1. Patients should be instructed to take larotrectinib exactly as prescribed, and not to adjust the dosage or discontinue treatment without the advice of a clinician. They should be told to swallow larotrectinib capsules whole, without chewing or crushing.

2. If a dose is missed, the patient should take it as soon as possible. However, if it is less than 6 hours until the next scheduled dose, the missed dose should not be taken. If vomiting occurs after administration, the next dose should be taken at the regularly scheduled time.

3. Patients should be informed of the risk of neurological adverse reactions. They should notify their clinician if they experience new or worsening neurological events (such as confusion, dizziness, impaired attention or memory, mood changes, sleep disorders, etc.). They should also be advised to avoid driving or operating hazardous machinery if neurological events occur.

from FDA，2022.11